These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32234423)

  • 1. Human variability in influx and efflux transporters in relation to uncertainty factors for chemical risk assessment.
    Darney K; Turco L; Buratti FM; Di Consiglio E; Vichi S; Roudot AC; Béchaux C; Testai E; Dorne JLCM; Lautz LS
    Food Chem Toxicol; 2020 Jun; 140():111305. PubMed ID: 32234423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment.
    Quignot N; Więcek W; Lautz L; Dorne JL; Amzal B
    Toxicol Lett; 2021 Feb; 337():111-120. PubMed ID: 33232775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Variability in Carboxylesterases and carboxylesterase-related Uncertainty Factors for Chemical Risk Assessment.
    Di Consiglio E; Darney K; Buratti FM; Turco L; Vichi S; Testai E; Lautz LS; Dorne JLCM
    Toxicol Lett; 2021 Oct; 350():162-170. PubMed ID: 34256091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human variability in polymorphic CYP2D6 metabolism: Implications for the risk assessment of chemicals in food and emerging designer drugs.
    Darney K; Lautz LS; Béchaux C; Wiecek W; Testai E; Amzal B; Dorne JLCM
    Environ Int; 2021 Nov; 156():106760. PubMed ID: 34256299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian meta-analysis of inter-phenotypic differences in human serum paraoxonase-1 activity for chemical risk assessment.
    Darney K; Kasteel EEJ; Buratti FM; Turco L; Vichi S; Béchaux C; Roudot AC; Kramer NI; Testai E; Dorne JLCM; Di Consiglio E; Lautz LS
    Environ Int; 2020 May; 138():105609. PubMed ID: 32114288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Yin-Yang of CYP3A4: a Bayesian meta-analysis to quantify inhibition and induction of CYP3A4 metabolism in humans and refine uncertainty factors for mixture risk assessment.
    Quignot N; Wiecek W; Amzal B; Dorne JL
    Arch Toxicol; 2019 Jan; 93(1):107-119. PubMed ID: 30298208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human variability in glutathione-S-transferase activities, tissue distribution and major polymorphic variants: Meta-analysis and implication for chemical risk assessment.
    Buratti FM; Darney K; Vichi S; Turco L; Di Consiglio E; Lautz LS; Béchaux C; Dorne JCM; Testai E
    Toxicol Lett; 2021 Feb; 337():78-90. PubMed ID: 33189831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
    Ebner T; Ishiguro N; Taub ME
    J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2005 Feb; 43(2):203-16. PubMed ID: 15621332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey.
    Kosa RE; Lazzaro S; Bi YA; Tierney B; Gates D; Modi S; Costales C; Rodrigues AD; Tremaine LM; Varma MV
    Drug Metab Dispos; 2018 Aug; 46(8):1179-1189. PubMed ID: 29880631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A scoping review of evaluations of and recommendations for default uncertainty factors in human health risk assessment.
    Johanson G; Moto TP; Schenk L
    J Appl Toxicol; 2023 Jan; 43(1):186-194. PubMed ID: 36017531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
    Dorne JL; Walton K; Slob W; Renwick AG
    Food Chem Toxicol; 2002 Nov; 40(11):1633-56. PubMed ID: 12176090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism and pharmacokinetics of pharmaceuticals in cats (Felix sylvestris catus) and implications for the risk assessment of feed additives and contaminants.
    Lautz LS; Jeddi MZ; Girolami F; Nebbia C; Dorne JLCM
    Toxicol Lett; 2021 Mar; 338():114-127. PubMed ID: 33253781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
    Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principles and Experimental Considerations for In Vitro Transporter Interaction Assays.
    Bhoopathy S; Bode C; Naageshwaran V; Weiskircher-Hildebrandt E; Mukkavilli V; Hidalgo IJ
    Methods Mol Biol; 2021; 2342():339-365. PubMed ID: 34272701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2003 Feb; 41(2):225-45. PubMed ID: 12480299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions.
    Zhang Q; Zhang Y; Boer J; Shi JG; Hu P; Diamond S; Yeleswaram S
    Drug Metab Dispos; 2017 Jun; 45(6):612-623. PubMed ID: 28283500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efflux transporter mRNA expression profiles in differentiating JEG-3 human choriocarcinoma cells as a placental transport model.
    Ikeda K; Yamasaki K; Homemoto M; Yamaue S; Ogawa M; Nakao E; Fukunaga Y; Nakanishi T; Utoguchi N; Myotoku M; Hirotani Y
    Pharmazie; 2012 Jan; 67(1):86-90. PubMed ID: 22393837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membrane transporter proteins: a challenge for CNS drug development.
    Girardin F
    Dialogues Clin Neurosci; 2006; 8(3):311-21. PubMed ID: 17117613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.
    Oshida K; Shimamura M; Seya K; Ando A; Miyamoto Y
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):117-128. PubMed ID: 26961540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.